CD38 monoclonal antibody (Isatuximab; (Bisht et al. 2023)) and inhibitors (Chini et al. 2018) are currently being used for treating patients with multiple myeloma and other cancers (Gao et al. 2021) and have been proposed for the treatment of neurodegeneration, based on the prediction that increasing NAD+ levels could be neuroprotective (Chini et al. 2018; Guerreiro et al. 2020). The gene discussed is CD38; the disease is plasma cell myeloma.